TitleAssistant Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Perez K, Jacene H, Hornick JL, Ma C, Vaz N, Brais LK, Alexander H, Baddoo W, Astone K, Esplin ED, Garcia J, Halperin DM, Kulke MH, Chan JA. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022 09 01; 29(9):533-544. PMID: 35731023.
      Citations:    Fields:    
    2. Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol. 2022 06 01; 8(6):904-909. PMID: 35389428.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    3. Landry JP, Clemente-Gutierrez U, Pieterman CRC, Chiang YJ, Waguespack SG, Jimenez C, Habra MA, Halperin DM, Fisher SB, Graham PH, Perrier ND. Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery. 2022 08; 172(2):559-566. PMID: 35437162.
      Citations:    Fields:    Translation:Humans
    4. Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdom Radiol (NY). 2022 Dec; 47(12):3962-3970. PMID: 35244755.
      Citations:    Fields:    
    5. Maxwell JE, Naraev B, Halperin DM, Choti MA, Halfdanarson TR. Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol. 2022 May; 29(5):3072-3084. PMID: 35165817.
      Citations:    Fields:    Translation:Humans
    6. Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Murage E, Wu R, Dennison JB, Krishna H, Peterson CB, Lozano G, Zhao H, Do KA, Halperin DM, Agarwal SK, Blau JE, Del Rivero J, Nilubol N, Walter MF, Welch JM, Weinstein LS, Vriens MR, van Leeuwaarde RS, van Treijen MJC, Valk GD, Perrier ND, Hanash SM. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2021 11 19; 106(12):e4969-e4980. PMID: 34318891.
      Citations: 2     Fields:    Translation:Humans
    7. Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Netw Open. 2021 10 01; 4(10):e2131744. PMID: 34705010.
      Citations: 1     Fields:    Translation:Humans
    8. Fujii Y, Tzeng CW, Chiang YJ, Halperin DM, Dasari A, Kim MP, Katz MHG, Lee JE, Ikoma N. Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. J Surg Res. 2021 12; 268:419-431. PMID: 34416414.
      Citations:    Fields:    Translation:Humans
    9. Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics. 2021 11; 39(11):1271-1297. PMID: 34378163.
      Citations:    Fields:    Translation:Humans
    10. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 07 28; 19(7):839-868. PMID: 34340212.
      Citations: 33     Fields:    Translation:Humans
    11. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747. PMID: 34261675.
      Citations: 8     Fields:    Translation:Humans
    12. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2022; 112(1):34-42. PMID: 33434908.
      Citations: 2     Fields:    Translation:Humans
    13. Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. 2021 Jan 01. PMID: 33480358.
      Citations: 17     Fields:    
    14. Hernandez Vargas S, Lin C, Voss J, Ghosh SC, Halperin DM, AghaAmiri S, Cao HST, Ikoma N, Uselmann AJ, Azhdarinia A. Development of a drug-device combination for fluorescence-guided surgery in neuroendocrine tumors. J Biomed Opt. 2020 12; 25(12). PMID: 33300316.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    15. Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY). 2022 Sep; 47(9):3078-3100. PMID: 33095312.
      Citations: 6     Fields:    
    16. Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas. 2020 10; 49(9):1123-1130. PMID: 32991344.
      Citations: 1     Fields:    Translation:Humans
    17. Shaunfield S, Webster KA, Kaiser K, Greene GJ, Yount SE, Lacson L, Benson AB, Halperin DM, Yao JC, Singh S, Feuilly M, Marteau F, Cella D. Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology. 2021; 111(9):850-862. PMID: 32911478.
      Citations: 1     Fields:    Translation:Humans
    18. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 08; 49(7):863-881. PMID: 32675783.
      Citations: 19     Fields:    Translation:Humans
    19. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas. 2020 07; 49(6):723-728. PMID: 32433264.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    20. Grubbs EG, Halperin DM, Waguespack SG, Gagel RF. History of the multiple endocrine neoplasia workshops and overview of MEN2019. Endocr Relat Cancer. 2020 Jun 01. PMID: 32508314.
      Citations: 2     Fields:    
    21. Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo WC, Richards DM, Halperin DM, Ge PS, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clin Colorectal Cancer. 2020 09; 19(3):e117-e123. PMID: 32284253.
      Citations: 1     Fields:    Translation:Humans
    22. Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer. 2020 04; 122(9):1309-1314. PMID: 32152503.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    23. Abu-Sbeih H, Mallepally N, Goldstein R, Chen E, Tang T, Dike UK, Al-Asadi M, Westin S, Halperin D, Wang Y. Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. J Cancer. 2020; 11(11):3144-3150. PMID: 32231718.
      Citations: 3     
    24. Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol. 2019 Dec 21; 25(47):6857-6865. PMID: 31885426.
      Citations: 3     Fields:    Translation:Humans
    25. Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas. 2019 Nov/Dec; 48(10):1373-1379. PMID: 31688604.
      Citations: 3     Fields:    Translation:Humans
    26. Naraev BG, Halland M, Halperin DM, Purvis AJ, O'Dorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas. 2019 09; 48(8):961-972. PMID: 31425482.
      Citations: 11     Fields:    Translation:Humans
    27. Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev Pharmacoecon Outcomes Res. 2020 Oct; 20(5):507-511. PMID: 31448649.
      Citations: 2     Fields:    Translation:Humans
    28. Samdani RT, Wasylishen AR, Halperin DM, Dasari A, Yao JC, Rashid A, Estrella JS. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas. 2019 04; 48(4):510-513. PMID: 30946241.
      Citations: 2     Fields:    Translation:HumansCells
    29. Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer. 2019 Mar 28; 19(1):274. PMID: 30922252.
      Citations: 5     Fields:    Translation:Humans
    30. Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas. 2019 03; 48(3):381-386. PMID: 30768575.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    31. Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol. 2018 12 12; 18(1):169. PMID: 30541475.
      Citations: 1     Fields:    Translation:Humans
    32. Wormser O, Gradstein L, Kadar E, Yogev Y, Perez Y, Mashkit E, Elbedour K, Drabkin M, Markus B, Kadir R, Halperin D, Khalaila S, Levy J, Lifshitz T, Manor E, Birk OS. Combined CNV, haplotyping and whole exome sequencing enable identification of two distinct novel EYS mutations causing RP in a single inbred tribe. Am J Med Genet A. 2018 12; 176(12):2695-2703. PMID: 30513137.
      Citations:    Fields:    Translation:Humans
    33. Balanescu DV, Donisan T, Lopez-Mattei J, Hassan S, Kim P, Dasari A, Halperin D, Yao J, Kar B, Gregoric I, Balanescu SM, Iliescu C. The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett. 2019 May; 17(5):4126-4132. PMID: 30944605.
      Citations: 2     
    34. Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study. Medicine (Baltimore). 2018 Nov; 97(47):e13390. PMID: 30461659.
      Citations: 3     Fields:    Translation:Humans
    35. Mijalovsky A, Halperin D, Perez Y, Zafarov B, Shaco-Levy R, Kapelushnik J, Flusser H, Birk OS. Malignant Peritoneal Mesothelioma in an Infant With Familial ATM Mutations. J Pediatr Hematol Oncol. 2018 11; 40(8):e511-e515. PMID: 30124550.
      Citations: 2     Fields:    Translation:Humans
    36. Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics. 2018 08; 36(8):1005-1013. PMID: 29682693.
      Citations: 3     Fields:    Translation:Humans
    37. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 06; 16(6):693-702. PMID: 29891520.
      Citations: 102     Fields:    Translation:Humans
    38. Cloyd JM, Omichi K, Mizuno T, Kawaguchi Y, Tzeng CD, Conrad C, Chun YS, Aloia TA, Katz MHG, Lee JE, Halperin D, Yao J, Vauthey JN, Dasari A. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol. 2018 Jun; 25(6):1709-1715. PMID: 29626307.
      Citations: 12     Fields:    Translation:Humans
    39. Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas. 2017 10; 46(9):1180-1187. PMID: 28902789.
      Citations: 21     Fields:    Translation:HumansCells
    40. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 01; 3(10):1335-1342. PMID: 28448665.
      Citations: 765     Fields:    Translation:Humans
    41. Mehrvarz Sarshekeh A, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget. 2017 11 21; 8(59):99541-99551. PMID: 29245922.
      Citations: 11     Fields:    
    42. Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462. PMID: 28642335.
      Citations: 13     Fields:    Translation:Humans
    43. Halperin DM, Shen C, Yao JC. Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. Lancet Oncol. 2017 06; 18(6):e300. PMID: 28593855.
      Citations: 1     Fields:    Translation:Humans
    44. Qiu W, Christakis I, Stewart AA, Vodopivec DM, Silva-Figueroa A, Chen H, Woodard TL, Halperin DM, Lee JE, Yao JC, Perrier ND. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1? Clin Endocrinol (Oxf). 2017 Jun; 86(6):791-797. PMID: 28273369.
      Citations: 5     Fields:    Translation:Humans
    45. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 04; 18(4):525-534. PMID: 28238592.
      Citations: 93     Fields:    Translation:Humans
    46. Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2017 01 20; 35(3):265-267. PMID: 27893328.
      Citations: 2     Fields:    Translation:Humans
    47. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, Dasari A, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2017 01; 21(1):155-163. PMID: 27634306.
      Citations: 12     Fields:    Translation:Humans
    48. Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas. 2016 07; 45(6):783-5. PMID: 27295529.
      Citations:    Fields:    Translation:HumansCells
    49. Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol. 2016 May; 3(2):175-189. PMID: 27347369.
      Citations: 3     
    50. Halperin DM, Yao JC. Clinical Trial Design in Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):209-17. PMID: 26614378.
      Citations: 1     Fields:    Translation:Humans
    51. Halperin DM, Dasari A, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. 2016 Feb; 12(3):313-21. PMID: 26759064.
      Citations: 2     Fields:    Translation:Humans
    52. Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol. 2015 Sep 10; 33(26):2914-9. PMID: 26261263.
      Citations:    Fields:    Translation:Humans
    53. Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703. PMID: 25956795.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    54. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015 Jun; 22(3):431-41. PMID: 25900182.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    55. Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med. 2015; 66:1-16. PMID: 25341008.
      Citations: 11     Fields:    Translation:Humans
    56. Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 02; 14:561. PMID: 25086465.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    57. Halperin DM, Varadhachary GR. Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter? Curr Oncol Rep. 2014 Feb; 16(2):366. PMID: 24445498.
      Citations: 9     Fields:    Translation:Humans
    58. Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 2012 Mar; 41(1):119-31. PMID: 22341253.
      Citations: 5     Fields:    Translation:Humans
    59. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas. 45:783-785.
    60. Phase i study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer. 22:431-441.
    61. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncology. 12:313-321.
    62. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery. 1-9.
    HALPERIN's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (213)
    Co-Authors (52)
    Similar People (60)
    Same Department Expand Description